Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...
Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it is initiating a Phase 2b study of narmafotinib in pancreatic cancer exploring a new dosing regimen.
Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...